Status:
RECRUITING
Precision Medicine in the Prostate Cancer Care Pathway
Lead Sponsor:
Institute of Cancer Research, United Kingdom
Collaborating Sponsors:
Royal Marsden NHS Foundation Trust
Conditions:
Prostate Cancer
Genetic Predisposition
Eligibility:
MALE
30-70 years
Brief Summary
This study aims to evaluate the use of a prostate cancer specific predisposition genetic panel test in men with / at high risk of prostate cancer. The genetic test will analyse men's DNA samples for t...
Eligibility Criteria
Inclusion
- Affected cohort:
- Affected with PrCa \< 60 years or
- Affected with metastatic castration resistant PrCa (mCRPC) at any age or Aggressive PrCa Gleason 4+4 or higher \<70 years
- Affected with family history defined as three or more cases any age (FDR or SDR)
- Unaffected cohort: (This cohort is no longer recruiting, it has completed recruitment)
- Aged \>30 and with a family history defined as:
- FDR diagnosed \< 70
- 2 or more cases in First or Second Degree Relatives (FDR/SDR) with one case diagnosed \< 70 years
- 3 or more cases at any age (on same side of family)
Exclusion
- • WHO performance status 4
Key Trial Info
Start Date :
February 14 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2034
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT04763317
Start Date
February 14 2019
End Date
December 1 2034
Last Update
December 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Marsden Hosital,
Sutton, England, United Kingdom, SM2 5PT